Business
Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors
Alva Therapeutics, Inc. ("Alva") a company developing a novel oral incretin secretagogue based therapy for the treatment of Type 2 diabetes and obesity—announced that Mr. Jesper Høiland has been appointed to Alva Board of Directors.
About this update from Scibase Holding Ab
[{"type":"text","content":"MILPITAS, Calif., Dec. 3, 2025 /PRNewswire/ -- Alva Therapeutics, Inc. ("Alva") a company developing a novel oral incretin secretagogue based therapy for the treatment of Type 2 diabetes and obesity—announced that Mr. Jesper Høiland has been appointed to Alva Board of Directors.","length":289,"tagName":"p"},{"type":"image","alt":"Alva Therapeutics Logo","displaySize":"","headline":null,"caption":"Alva Therapeutics Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/497787a46f4e063219ccd44e1f8c4043"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1zzD7QKLByiR2N3ta9o9SA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/497787a46f4e063219ccd44e1f8c4043","width":400,"height":400},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/3Oqnk2au993RpCLWSj9DNw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/497787a46f4e063219ccd44e1f8c4043","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2836853/Alva_Therapeutics__Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Mr. Jesper Høiland is a seasoned industry leader with over three decades of experience across senior leadership positions at Novo Nordisk. Throughout his 30-year career at Novo Nordisk, culminating in executive roles including EVP and President, Mr. Høiland guided the company through key commercialization initiatives, product launches, and strategic growth operations.","length":370,"tagName":"p"},{"type":"text","content":"Mr. Høiland previously served as President and CEO of Radius Health and as former Global Commercial Officer at Ascendis Pharma, where he oversaw major pharmaceutical commercialization efforts. Currently, Mr. Høiland serves as Chairman of SciBase Holding AB and is a board member of ALK-Abell ó A/S, Flen Health SA, and Allarity Therapeutics.","length":346,"tagName":"p"},{"type":"text","content":""It is my distinct pleasure to welcome Jesper Høiland to the Alva Board of Directors," said Mir Imran, CEO and Chairman of the Board of Directors of Alva Therapeutics. Mr. Imran added, "Jesper brings decades of experience and knowledge in guiding pharmaceutical product launches in the diabetes space. His contributions...